• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

HER2/neu in the management of invasive breast cancer.

作者信息

Meric Funda, Hung Mien-Chie, Hortobagyi Gabriel N, Hunt Kelly K

机构信息

Department of Surgical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, 77030, USA.

出版信息

J Am Coll Surg. 2002 Apr;194(4):488-501. doi: 10.1016/s1072-7515(02)01121-3.

DOI:10.1016/s1072-7515(02)01121-3
PMID:11949754
Abstract
摘要

相似文献

1
HER2/neu in the management of invasive breast cancer.
J Am Coll Surg. 2002 Apr;194(4):488-501. doi: 10.1016/s1072-7515(02)01121-3.
2
Predicting response to herceptin therapy.预测对赫赛汀治疗的反应。
Clin Cancer Res. 2004 Mar 1;10(5):1559-60. doi: 10.1158/1078-0432.ccr-1221-3.
3
Her2 and trastuzumab in breast cancer.人表皮生长因子受体2（Her2）与曲妥珠单抗在乳腺癌中的作用
Cancer Control. 2001 Jan-Feb;8(1):103-10. doi: 10.1177/107327480100800113.
4
HER2 status and benefit from adjuvant trastuzumab in breast cancer.HER2状态与乳腺癌辅助性曲妥珠单抗治疗的获益情况
N Engl J Med. 2008 Mar 27;358(13):1409-11. doi: 10.1056/NEJMc0801440.
5
Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer.曲妥珠单抗（赫赛汀）治疗转移性乳腺癌的疗效概述。
Semin Oncol. 2001 Dec;28(6 Suppl 18):43-7.
6
Another ingredient added to HER2 mix.另一种添加到HER2混合物中的成分。
CAP Today. 1999 Nov;13(11):1, 20-4, 26 passim.
7
Will single-time tumor profiling and a "guilt by association" approach allow us to outsmart HER2-positive breast cancer?单次肿瘤分析和“关联定罪”方法能让我们在应对HER2阳性乳腺癌时技高一筹吗？
Clin Cancer Res. 2007 Feb 15;13(4):1071-3. doi: 10.1158/1078-0432.CCR-06-2717.
8
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.HER2受体截短形式p95HER2的表达及乳腺癌中抗HER2治疗的反应
J Natl Cancer Inst. 2007 Apr 18;99(8):628-38. doi: 10.1093/jnci/djk134.
9
Proceedings of the HER2 State of the Art Conference. 21-23 November 1999. Montreux, Switzerland.
Ann Oncol. 2001;12 Suppl 1:1-107.
10
HER2 and surgery: more questions to answer.人表皮生长因子受体2与手术：更多问题有待解答。
Lancet. 2003 Aug 16;362(9383):502-3. doi: 10.1016/S0140-6736(03)14147-5.

引用本文的文献

1
HER-2 ultra-low breast cancer: exploring the clinicopathological features and prognosis in a retrospective study.HER-2超低位乳腺癌：一项回顾性研究中临床病理特征及预后的探索
Front Oncol. 2023 Aug 17;13:1210314. doi: 10.3389/fonc.2023.1210314. eCollection 2023.
2
Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention.恢复乳腺癌中丧失的抗HER-2 Th1免疫：Th1细胞因子在治疗和预防中的关键作用
Front Pharmacol. 2016 Oct 6;7:356. doi: 10.3389/fphar.2016.00356. eCollection 2016.
3
Progressive loss of anti-HER2 CD4 T-helper type 1 response in breast tumorigenesis and the potential for immune restoration.
乳腺肿瘤发生过程中抗HER2 CD4辅助性1型T细胞反应的渐进性丧失及免疫恢复的潜力
Oncoimmunology. 2015 Apr 1;4(10):e1022301. doi: 10.1080/2162402X.2015.1022301. eCollection 2015 Oct.
4
AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer.AMP激活蛋白激酶（AMPK）调节乳腺癌中HER2和表皮生长因子受体（EGFR）的活性。
Oncotarget. 2015 Jun 20;6(17):14754-65. doi: 10.18632/oncotarget.4474.
5
Anti-HER2 CD4(+) T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer.抗HER2 CD4(+) 1型辅助性T细胞应答是HER2阳性乳腺癌新辅助治疗后病理反应的一种新型免疫相关指标。
Breast Cancer Res. 2015 May 23;17(1):71. doi: 10.1186/s13058-015-0584-1.
6
Malignant transformation of rat kidney induced by environmental substances and estrogen.环境物质和雌激素诱发大鼠肾恶性转化。
Int J Environ Res Public Health. 2012 May;9(5):1630-48. doi: 10.3390/ijerph9051630. Epub 2012 May 4.
7
Silencing of Her2, CCNB1 and PKC Genes by siRNA Results in Prolonged Retardation of Neuroblastoma Cell Division.通过 siRNA 沉默 Her2、CCNB1 和 PKC 基因可导致神经母细胞瘤细胞分裂的长期延缓。
Acta Naturae. 2011 Jul;3(3):29-39.
8
Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.拉帕替尼联合卡培他滨治疗拉帕替尼扩展使用项目中的 HER2 阳性转移性乳腺癌，包括脑转移的疗效——英国经验。
Br J Cancer. 2010 Mar 16;102(6):995-1002. doi: 10.1038/sj.bjc.6605586. Epub 2010 Feb 23.
9
Rapamycin effects on mTOR signaling in benign, premalignant and malignant human breast epithelial cells.雷帕霉素对人良性、癌前和恶性乳腺上皮细胞中mTOR信号传导的影响。
Anticancer Res. 2009 Apr;29(4):1143-50.
10
Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications.晚期乳腺癌中的趋化因子受体：在转移病灶部位的差异表达及其诊断和治疗意义
Ann Oncol. 2009 Jun;20(6):1013-9. doi: 10.1093/annonc/mdn740. Epub 2009 Feb 23.